Nanoparticles aim to reverse lung rejection in transplant patients
NCT ID NCT07234760
First seen Nov 18, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tested a new way to deliver the drug everolimus directly to the lungs using tiny particles called liposomes. The goal was to treat chronic lung rejection (bronchiolitis obliterans syndrome) after a lung transplant. Researchers worked with cells and lung tissue from 19 transplant patients to see if this targeted approach could reduce side effects and better control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS SYNDROME (BOS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardy, 27100, Italy
Conditions
Explore the condition pages connected to this study.